Emergent BioSolutions Files 8-K: Material Agreement & Financial Update

TL;DR

Emergent BioSolutions signed a big deal, expect financial updates soon.

AI Summary

Emergent BioSolutions Inc. reported on September 30, 2024, that it entered into a material definitive agreement. The company also disclosed its results of operations and financial condition, and created a direct financial obligation. This filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.

Why It Matters

This 8-K filing indicates a significant new agreement for Emergent BioSolutions, which could impact its financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements and financial condition disclosures can introduce uncertainty and potential volatility for investors.

Key Players & Entities

• Emergent BioSolutions Inc. (company) — Registrant
• September 30, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-33137 (identifier) — Commission File Number
• 14-1902018 (identifier) — IRS Employer Identification No.
• 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Principal executive offices
• 240-631-3200 (phone_number) — Business phone

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share EBS New York St
• $100 m — ving Loans") of up to the lesser of (x) $100 million, which may be increased (but not
• $125 m — , which may be increased (but not above $125 million, or the "Maximum Revolver Amount"
• $50 million — er Amount") or decreased (but not below $50 million) by the Borrowers in accordance with th
• $5 million — he facility may not be increased. Up to $5 million of capacity under the Revolving Loans m
• $10 million — s may be used for swing loans and up to $10 million may be used for the issuance of letters

Filing Documents

• d825659d8k.htm (8-K) — 35KB
• d825659dex101.htm (EX-10.1) — 1017KB
• d825659dex991.htm (EX-99.1) — 7KB
• 0001193125-24-230710.txt ( ) — 1434KB
• ebs-20240930.xsd (EX-101.SCH) — 3KB
• ebs-20240930_lab.xml (EX-101.LAB) — 17KB
• ebs-20240930_pre.xml (EX-101.PRE) — 11KB
• d825659d8k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Credit Agreement, dated as of September 30, 2024, by and among Emergent BioSolutions Inc., certain of its subsidiaries, as borrowers, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the agent. 99.1 Press release issued by Emergent BioSolutions Inc. on October 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified information is (i) not material and (ii) the type of information that the registrant treats as private or confidential.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: October 2, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR